Compare Cadila Healthcare with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SANOFI INDIA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SANOFI INDIA CADILA HEALTHCARE/
SANOFI INDIA
 
P/E (TTM) x 34.7 39.5 87.9% View Chart
P/BV x 6.1 8.0 75.7% View Chart
Dividend Yield % 0.6 1.1 52.3%  

Financials

 CADILA HEALTHCARE   SANOFI INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
SANOFI INDIA
Dec-18
CADILA HEALTHCARE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3526,840 5.2%   
Low Rs2074,630 4.5%   
Sales per share (Unadj.) Rs139.21,203.1 11.6%  
Earnings per share (Unadj.) Rs11.8165.3 7.1%  
Cash flow per share (Unadj.) Rs18.6209.9 8.8%  
Dividends per share (Unadj.) Rs3.5084.00 4.2%  
Dividend yield (eoy) %1.31.5 85.5%  
Book value per share (Unadj.) Rs101.4963.6 10.5%  
Shares outstanding (eoy) m1,023.7423.03 4,445.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x2.04.8 42.1%   
Avg P/E ratio x23.734.7 68.4%  
P/CF ratio (eoy) x15.027.3 55.1%  
Price / Book Value ratio x2.86.0 46.3%  
Dividend payout %29.850.8 58.5%   
Avg Mkt Cap Rs m286,033132,078 216.6%   
No. of employees `00013.43.3 406.1%   
Total wages/salary Rs m24,1454,068 593.5%   
Avg. sales/employee Rs Th10,632.78,393.8 126.7%   
Avg. wages/employee Rs Th1,801.21,232.4 146.2%   
Avg. net profit/employee Rs Th898.51,153.0 77.9%   
INCOME DATA
Net Sales Rs m142,53127,708 514.4%  
Other income Rs m1,139897 127.0%   
Total revenues Rs m143,67028,605 502.3%   
Gross profit Rs m24,1986,235 388.1%  
Depreciation Rs m6,9651,027 678.2%   
Interest Rs m3,4187 48,828.6%   
Profit before tax Rs m14,9546,098 245.2%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1982,292 139.5%   
Profit after tax Rs m12,0443,806 316.4%  
Gross profit margin %17.022.5 75.4%  
Effective tax rate %21.437.6 56.9%   
Net profit margin %8.513.7 61.5%  
BALANCE SHEET DATA
Current assets Rs m87,15415,922 547.4%   
Current liabilities Rs m82,6946,235 1,326.3%   
Net working cap to sales %3.135.0 9.0%  
Current ratio x1.12.6 41.3%  
Inventory Days Days7164 112.2%  
Debtors Days Days9421 449.6%  
Net fixed assets Rs m133,2367,539 1,767.3%   
Share capital Rs m1,024230 445.2%   
"Free" reserves Rs m102,73321,962 467.8%   
Net worth Rs m103,75722,192 467.5%   
Long term debt Rs m32,1460-   
Total assets Rs m236,86629,839 793.8%  
Interest coverage x5.4872.1 0.6%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.9 64.8%   
Return on assets %6.512.8 51.1%  
Return on equity %11.617.2 67.7%  
Return on capital %13.727.5 49.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,7527,587 695.3%   
Fx outflow Rs m14,5047,145 203.0%   
Net fx Rs m38,248442 8,653.4%   
CASH FLOW
From Operations Rs m25,0543,739 670.1%  
From Investments Rs m-10,123-731 1,384.8%  
From Financial Activity Rs m-10,942-1,972 554.9%  
Net Cashflow Rs m3,9891,036 385.0%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.3 14.4 57.6%  
FIIs % 5.9 14.6 40.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 15,184 290.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   UNICHEM LAB  AUROBINDO PHARMA  STERLING BIOTECH  DR. DATSONS LABS  ELDER PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 14, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS